Sue Leurgans to Antiparkinson Agents
This is a "connection" page, showing publications Sue Leurgans has written about Antiparkinson Agents.
Connection Strength
0.701
-
Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008 Apr 15; 23(5):690-9.
Score: 0.292
-
Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Clin Neuropharmacol. 2009 Jul-Aug; 32(4):189-92.
Score: 0.079
-
Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord. 2006 Feb; 21(2):267-70.
Score: 0.063
-
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002 May 14; 58(9):1418-22.
Score: 0.048
-
Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord. 2002 Mar; 17(2):283-8.
Score: 0.048
-
Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol. 2001 Sep; 58(9):1379-82.
Score: 0.046
-
Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology. 2000 Jan 25; 54(2):458-62.
Score: 0.041
-
Two-year exercise program improves physical function in Parkinson's disease: the PRET-PD randomized clinical trial. Neurorehabil Neural Repair. 2015 Feb; 29(2):112-22.
Score: 0.028
-
Evaluating Parkinson's disease patients at home: utility of self-videotaping for objective motor, dyskinesia, and ON-OFF assessments. Mov Disord. 2008 Jul 30; 23(10):1479-82.
Score: 0.019
-
Dopaminergic hypersensitivity in patients with Parkinson disease and migraine. Clin Neuropharmacol. 2004 Jan-Feb; 27(1):30-2.
Score: 0.014
-
Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol. 2003 Apr; 60(4):529-33.
Score: 0.013
-
Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol. 1998 Sep-Oct; 21(5):289-95.
Score: 0.009